Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
- New partnership model leverages Aptar Digital Health’s capabilities to support the development and operation of new and existing digital health solutions globally
- Initial scope of multi-year agreement covers several indications in neurology and immunology across 15 countries
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240209478696/en/
Graphic: Aptar Signs Enterprise Agreement with Biogen to Operate and Develop Digital Health Solutions
Through this collaboration, Aptar will provide a full range of capabilities including the product management, design, development and maintenance of software applications, secured cloud hosting, and customer and marketing support to Biogen.
Over the past years, Biogen has successfully launched several flagship digital health solutions which have supported hundreds of thousands of patients in over 15 countries. The first solutions to transition to an operation by Aptar in
- Cleo™/Aby™: a digital care companion app to help people live with multiple sclerosis. It includes disease information, symptom-tracking, treatment reminders and tailored self-care programs on topics like fatigue and emotional management.
- Physio.me: a digital exercise companion that offers at-home, tailored exercises to patients with neuromuscular disorders who can measure and share their progress with their care team and can increase their likelihood to achieve their physical goals.
In addition to these solutions, Biogen and Aptar will further collaborate to potentially develop and bring to market new digital health solutions for the management of spinal muscular amyotrophy, Friedreich’s ataxia and lupus in selected countries.
“We are excited to leverage our end-to-end capabilities to support Biogen and enable patients and their care teams to benefit from advanced digital solutions for better disease management,”said
“Biogen is a recognized pharmaceutical leader who has been at the forefront of digital health in neuroscience over the past years,”stated
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care.
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240209478696/en/
Aptar Investor Relations Contact:
mary.skafidas@aptar.com
+1 347 351 6407
Aptar Pharma Media Contact:
carolyn.penot@aptar.com
+ 33 6 37 36 76 84
Aptar Media Contact:
katie.reardon@aptar.com
+1 815 479 5671
Source: